Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Ranbaxy Had Smaller Recall of Generic Lipitor in August Over Pill Mix-up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/29/2012 | 06:27pm CEST
   By Peter Loftus 
 

Ranbaxy Laboratories Ltd. (500359.BY) recalled more than 32,000 bottles of its generic version of cholesterol-lowering drug Lipitor over a potential pill mix-up in August--nearly three months before a larger recall for the presence of small glass particles in some bottles.

The retail-level recall in August was triggered by a pharmacist's discovery of a 20-milligram tablet of atorvastatin--the generic name for Lipitor--inside a sealed bottle of 10-mg atorvastatin, according to details posted online this week by the U.S. Food and Drug Administration.

In an August letter to customers initiating the voluntary recall of one product lot, Ranbaxy said it couldn't rule out the possibility that the pill mix-up occurred at its facility.

The FDA has now designated the August recall as Class 2, which is reserved for situations when use of a drug may cause temporary or medically reversible health problems, or where the probability of serious adverse events is remote.

The lot recalled in August was Ranbaxy's 10-mg, 90-count tablets, with lot number 2407258 and an expiration date May 2014, according to the FDA.

Ranbaxy spokesmen couldn't immediately be reached Thursday.

The mixed-pill recall preceded a separate, larger Ranbaxy recall earlier in November of 41 lots of its generic atorvastatin, because some may have contained tiny glass particles resembling fine grains of sand. Neither Ranbaxy nor the FDA have said how many bottles in total were recalled in the latest action.

Ranbaxy, which holds more than 40% of the U.S. market for atorvastatin prescriptions, said in a press release Wednesday the probability of an adverse health event due to consumption of the tablets recalled for potential glass particles is unlikely, but can't be ruled out.

Ranbaxy said it hadn't received any reports of adverse events related to the more recent recall. The affected lot numbers in the more recent recall can be found here: http://ranbaxyusa.com/newsdisp281112.aspx.

The FDA said in a statement Thursday Ranbaxy has stopped manufacturing atorvastatin until it has investigated the cause of the glass particles and fixed the problem. The FDA said it doesn't anticipate a shortage because generic Lipitor is available from several manufacturers. But the agency is monitoring the situation and is working with other manufacturers to ensure adequate supply.

Ranbaxy was one of the first companies to begin selling generic Lipitor in the U.S. a year ago, after Pfizer Inc. (>> Pfizer Inc.) lost market exclusivity for the branded version of the drug. Pfizer's Lipitor was once the best-selling drug in the world, but sales have plummeted as it lost market share to multiple generic alternatives.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
04:55p AstraZeneca lung cancer failure sparks 16 percent share fall
01:21p PFIZER : Kentwood Police Department receives overdose-combatting kits
07/26 PFIZER : Second US infliximab biosimilar launched at 35% discount to J&Js Remica..
07/26 PFIZER : Merck and Pfizer Collaborate with Corning
07/25 PFIZER : The Hill - Discussion
07/25 VIIV HEALTHCARE : Announces Superior Efficacy of Dolutegravir Versus Lopinavir/R..
07/25 PFIZER : Backed by partners at Pfizer, eFFECTOR brings its VC total to $150M as ..
07/25 PFIZER : Corning, with assists from Pfizer and Merck, plans $500M pharma glass p..
07/25 PFIZER : Phase II Study Results Showed Comparable Viral Suppression Rates at 96 ..
07/25 PFIZER : Announces Positive Top-Line Results From Comparative Reflections B73910..
More news
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Financials ($)
Sales 2017 52 763 M
EBIT 2017 19 898 M
Net income 2017 10 910 M
Debt 2017 23 332 M
Yield 2017 3,90%
P/E ratio 2017 16,70
P/E ratio 2018 14,90
EV / Sales 2017 4,15x
EV / Sales 2018 3,87x
Capitalization 195 864 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 37,4 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Ole Isacson Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC195 864
JOHNSON & JOHNSON14.47%352 757
NOVARTIS7.69%222 032
ROCHE HOLDING LTD.4.08%220 038
PFIZER1.91%195 864
MERCK AND COMPANY4.98%169 033